Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/3/2025

Cardiac Effects of Dapsone

Primary Cardiac Manifestations

  • Methemoglobinemia impairs oxygen delivery to cardiac tissue by oxidizing hemoglobin iron from the ferrous (Fe2+) to ferric (Fe3+) state, preventing effective oxygen binding and transport, according to the American Heart Association guidelines 1
  • Cardiovascular collapse and death can occur with severe methemoglobinemia, though this typically requires methemoglobin levels exceeding 50-70% in otherwise healthy individuals, as reported in Circulation 1

Risk Stratification and Monitoring

  • G6PD deficiency screening is mandatory before initiating dapsone therapy, particularly in males of African, Mediterranean, or Asian ancestry, as recommended by the American College of Medical Genetics 2, 3

Management of Cardiac Complications

  • Methylene blue (1-2 mg/kg IV) is the definitive treatment for symptomatic methemoglobinemia, acting as a cofactor to reduce methemoglobin back to hemoglobin, as stated in the Circulation guidelines 1

Critical Drug Interactions Affecting Cardiac Risk

  • Cotrimoxazole (trimethoprim-sulfamethoxazole) increases the risk of dapsone toxicity, including methemoglobinemia, requiring more frequent monitoring if co-administered, as warned by the European Respiratory Society 4

Dosing Considerations for Cardiac Safety

  • Starting at lower doses (50 mg daily) and titrating upward minimizes hematologic side effects while maintaining therapeutic benefit, particularly important in patients with cardiac disease, as recommended by the American College of Cardiology 3
  • Most patients with dermatologic conditions are controlled on 100 mg daily or less, avoiding the higher hemolysis risk associated with doses exceeding 200 mg daily, as suggested by the American Academy of Dermatology 2, 3